

PATENT
Attorney Docket No. PSU-04423

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hopper *et al.*

Serial No.: 09/599,662

Group No.:

Filed: 06/22/00

Examiner:

Entitled: **Compositions and Methods for the
Quantification of Sterol Biosynthetic Flux**

**AMENDMENT IN RESPONSE TO
NOTICE TO COMPLY WITH
SEQUENCE RULES MAILED 03/05/01**

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Dated: May 4, 2001

By: Marilyn Moy

Marilyn Moy

Sir or Madam:

This document is submitted in response to the Examiner's notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, mailed March 5, 2001 and setting two months for a response.

A clean version of the rewritten, added, and/or cancelled text with instructions for entry pursuant to 37 C.F.R. §1.121 is included beginning on page 2 of this communication. A marked-up version of the rewritten, added, and/or cancelled text pursuant to 37 C.F.R. §1.121 is attached as Appendix I.

CLEAN VERSION OF REWRITTEN, ADDED, AND/OR CANCELLED
TEXT PURSUANT TO 37 C.F.R. §1.121 (b)

Please replace the paragraph beginning on page 8, lines 18-21, with the following text:

Figure 4 (SEQ ID NOS: 1-5) presents selected mutations introduced into the *MOD5* gene and oligonucleotides. See, Gillman *et al.*, "*MOD5* translation initiation sites determine N6-isopentenyladenosine modification of mitochondrial and cytoplasmic tRNA", "*Mol Cell Biol* 11:2382-2390.

Please insert the attached Sequence Listing as new pages --40-42--.

IN THE FIGURES:

Please replace Figure 4 with the attached Figure 4 Substitute Sheet.

IN THE CLAIMS:

Please renumber the Claims pages from pages "40-42" to --43-45--.

IN THE ABSTRACT OF THE DISCLOSURE:


Please renumber the Abstract page from page "43" to --46--.

R E M A R K S

Applicants submit this Amendment to provide as a separate part of the disclosure, a "Sequence Listing" pursuant to 37 C.F.R. §§ 1.821-1.825. As such, Applicants submit that no new matter has been introduced by these amendments. In addition, Applicants submit herewith in paper copy and on floppy disk the Sequence Listing in computer readable form. Applicants respectfully request entry of this Amendment.

In order to add the Sequence Identification Numbers to Figure 4, Applicants provide new Figure 4 (*i.e.*, a Substitute Sheet) for entry. Per 37 C.F.R. §1.121(d), a marked-up copy showing the changes in red is also included herewith. Should the Examiner have any questions regarding these amendments, the Examiner is encouraged to call the undersigned collect.

Dated: 4 May 2001


Kamrin T. MacKnight
Registration No. 38,230

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
415.705.8410



APPENDIX I
MARKED-UP VERSION OF REWRITTEN, ADDED,
AND/OR CANCELLED TEXT

The following is a version of the text pursuant to 37 C.F.R. §1.121, with markings showing changes made herein to the previous version of record of the Specification.

Please replace the paragraph on page 8, lines 18-21, as follows:

Figure 4 (SEQ ID NOS: 1-5) presents selected mutations introduced into the *MOD5* gene and oligonucleotides. See, Gillman *et al.*, "*MOD5* translation initiation sites determine N6-isopentenyladenosine modification of mitochondrial and cytoplasmic tRNA", "*Mol Cell Biol* 11:2382-2390.

0959662-050701